## Abstract The tumor microenvironment, composed of nonβcancer cells and their stroma, has become recognized as a major factor influencing the growth of cancer. The microenvironment has been implicated in the regulation of cell growth, determining metastatic potential and possibly determining locat
The role of tumor stroma in the interaction between tumor and immune system
β Scribed by Thomas Blankenstein
- Publisher
- Elsevier Science
- Year
- 2005
- Tongue
- English
- Weight
- 147 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0952-7915
No coin nor oath required. For personal study only.
β¦ Synopsis
It is often assumed that tumor rejection is mainly the result of cytotoxic T lymphocytes (CTLs) killing the tumor cells. However, recent studies have demonstrated that the rejection process is not as simple as this. In some models, tumors are rejected in the absence of lytic mechanisms (e.g. perforin or Fas ligand), and in others CTLs kill tumor stromal cells that cross-present antigen. T cells with lytic function but IFN-g deficiency rarely reject tumors. IFN-g and, in some models, other T-cell cytokines such as TNF-a, IL-4 or IL-10 contribute to tumor rejection by inhibition of tumor stroma formation. These cytokines inhibit tumor-induced angiogenesis, probably through different cellular targets.
π SIMILAR VOLUMES
Well-established solid tumors (at least 14 days old and >1 cm in average diameter) are extremely difficult to eradicate immunologically in mice. Most cancer patients that seek medical attention bear primary or metastatic tumors that have grown for longer and that are larger than the tumors we call e
## Abstract The fact that certain tumors exhibit a predilection for metastasis to specific organs has been recognized for well over a century now. An extensive body of clinical data and experimental research has confirmed Stephen Paget's original βseed and soilβ hypothesis that proposed the organβp
## Abstract This review summarizes some recent clinical immunological approaches with cytokines and/or antibodies for therapy of advanced breast cancer. It considers the recent advances in genetics and molecular tumor biology related to impaired immunosurveillance involving cytokines and growth fac